Literature DB >> 28881921

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J B A G Haanen1, F Carbonnel2, C Robert3, K M Kerr4, S Peters5, J Larkin6, K Jordan7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28881921     DOI： 10.1093/annonc/mdx225

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  485 in total

1.  Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.

Authors:  Emily Coleman; Christine Ko; Feng Dai; Mary M Tomayko; Harriet Kluger; Jonathan S Leventhal
Journal:  J Am Acad Dermatol       Date:  2018-11-03       Impact factor: 11.527

2.  Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board.

Authors:  Laura C Kennedy; Kit Man Wong; Nikhil V Kamat; Ali Raza Khaki; Shailender Bhatia; John A Thompson; Petros Grivas
Journal:  Target Oncol       Date:  2020-08       Impact factor: 4.493

Review 3.  Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies.

Authors:  Ignacio Morales-Orue; Rodolfo Chicas-Sett; Pedro C Lara
Journal:  Rep Pract Oncol Radiother       Date:  2018-11-22

Review 4.  Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Authors:  Christophoros Astaras; Rita de Micheli; Bianca Moura; Thomas Hundsberger; Andreas F Hottinger
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-01       Impact factor: 5.081

Review 5.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

Review 6.  Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.

Authors:  Kristen E Pauken; Michael Dougan; Noel R Rose; Andrew H Lichtman; Arlene H Sharpe
Journal:  Trends Immunol       Date:  2019-04-30       Impact factor: 16.687

7.  Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.

Authors:  Kerry L Reynolds; Amanda C Guidon
Journal:  Oncologist       Date:  2018-11-27

Review 8.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

9.  Emergency room imaging in patients with genitourinary cancers: analysis of the spectrum of CT findings and their relation to patient outcomes.

Authors:  Sungmin Woo; Jad Bou Ayache; Peter Sawan; Julian Infantino; Natalie Gangai; Andreas Wibmer; Hedvig Hricak; Jeffrey S Groeger; Hebert Alberto Vargas
Journal:  Emerg Radiol       Date:  2020-04-06

10.  Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis.

Authors:  Janet Roberts; Michael Smylie; John Walker; Naveen S Basappa; Quincy Chu; Michael Kolinsky; Christopher Lyddell; Carrie Ye
Journal:  Clin Rheumatol       Date:  2019-01-30       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.